Date | Price Target | Rating | Analyst |
---|---|---|---|
11/20/2023 | $15.00 | Neutral | JP Morgan |
8/28/2023 | $85.00 → $25.00 | Buy → Neutral | H.C. Wainwright |
8/8/2023 | $45.00 | Neutral → Overweight | Piper Sandler |
8/4/2023 | $51.00 | Outperform | SVB Securities |
7/31/2023 | $33.00 | Underperform → In-line | Evercore ISI |
6/7/2023 | $53.00 → $46.00 | Underperform → Neutral | Wedbush |
5/16/2023 | $70.00 → $104.00 | Equal Weight → Overweight | Wells Fargo |
3/17/2023 | $99.00 → $50.00 | Neutral → Underweight | JP Morgan |
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ:NVCR) today reported financial results for the quarter ended June 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "The second quarter was a period of consistent execution at Novocure," said Asaf Danziger, Novocure's Chief Executive Officer. "We began the year with three k
Novocure (NASDAQ:NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company's financial results for the three and six months ended June 30, 2024, at 8:00 a.m. EDT on Thursday, July 25, 2024. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of
Quarterly net revenues of $139 million, up 13% year-over-year, with 3,845 active patients on therapy as of March 31, 2024 Phase 3 METIS trial in brain metastases from non-small cell lung cancer met primary endpoint and will be presented as late-breaking abstract at ASCO 2024 LUNAR PMA application for TTFields in NSCLC Day 100 FDA meeting complete Novocure (NASDAQ:NVCR) today reported financial results for the quarter ended March 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "The first quarter was a period of strong ex
8-K - NovoCure Ltd (0001645113) (Filer)
S-8 POS - NovoCure Ltd (0001645113) (Filer)
S-8 POS - NovoCure Ltd (0001645113) (Filer)
4 analysts have expressed a variety of opinions on NovoCure (NASDAQ:NVCR) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 1 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $23.0, a high estimate of $2
Evercore ISI Group analyst Vijay Kumar maintains NovoCure (NASDAQ:NVCR) with a In-Line and raises the price target from $14.5 to $20.
JP Morgan resumed coverage of NovoCure with a rating of Neutral and set a new price target of $15.00
H.C. Wainwright downgraded NovoCure from Buy to Neutral and set a new price target of $25.00 from $85.00 previously
Piper Sandler upgraded NovoCure from Neutral to Overweight and set a new price target of $45.00
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
Novocure (NASDAQ:NVCR) announced today it will present a real-world analysis of usage of its Tumor Treating Fields (TTFields) therapy and survival outcomes in newly diagnosed glioblastoma (ndGBM) patients at the European Society for Medical Oncology (ESMO) Congress 2024, September 13 – 17, Barcelona, Spain. The results of the real-world analysis suggest higher TTFields therapy device usage is significantly associated with improved survival outcomes in a broad population of ndGBM patients. Novocure's ESMO 2024 Data Presentation Details: Poster #459: Association of Tumor Treating Fields Device Usage with Survival in Newly Diagnosed GBM: A Real-World Analysis of Patients in the US Authors:
After 22 years as CEO, Asaf Danziger to retire at year end, will be succeeded by current CFO Ashley Cordova Wilco Groenhuysen to step down after 12 years as COO, Mukund Paravasthu current Senior Vice President, Product Development to transition to COO Novocure (NASDAQ:NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure's Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company's next CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903420700/en/Asaf Danziger, Chief Executive Officer (Photo: Business Wire) Mr. Danziger, who has served a
Novocure (NASDAQ:NVCR) announced today that management will participate in the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024. William Doyle, Novocure's Executive Chairman, will take part in a fireside chat at 4:30 p.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of this presentation can be accessed from the Investor Relations page of Novocure's website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event. Novocure's corporate presentation is updated periodically, and the current presentation can be accessed from the Investor Relations page of Novocure's w
After 22 years as CEO, Asaf Danziger to retire at year end, will be succeeded by current CFO Ashley Cordova Wilco Groenhuysen to step down after 12 years as COO, Mukund Paravasthu current Senior Vice President, Product Development to transition to COO Novocure (NASDAQ:NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure's Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company's next CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903420700/en/Asaf Danziger, Chief Executive Officer (Photo: Business Wire) Mr. Danziger, who has served a
Medical Device Leaders Shlomi Nachman and Timothy Scannell to join Board of DirectorsBOSTON, July 16, 2024 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, today announced the following appointments to the Company's Board of Directors, effective July 11, 2024: Shlomi Nachman, former Company Group Chairman of Cardiovascular and Specialty Solutions and Vision Groups within Johnson & Johnson's Medical Devices sectorTimothy Scannell, former President and Chief Operating Officer of Stryker"We are excited
Novocure (NASDAQ:NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer. Dr. Leupin brings a proven track record of leadership and accomplishment in the biotechnology and pharmaceutical industries, as well as extensive experience as a medical oncologist and educator. At Novocure, Dr. Leupin will oversee medical affairs, medical safety, and clinical development operations as the company advances its clinical pipeline and prepares to treat an expanded patient population. "It is a pleasure to welcome Dr. Leupin to Novocure as our new Chief Medical Officer," said Asaf Danziger, Novocure's Chief Executive Officer. "Nicolas brings a wealth